Please cite this article as: Demeter, Z., Palade, E.A., Hornyák,Á., Rusvai, M., Controversial results of the genetic analysis of a canine distemper vaccine strain, Veterinary Microbiology (2008Microbiology ( ), doi:10.1016Microbiology ( /j.vetmic.2009 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. 
M a n u s c r i p t 
Vaccine batches 7
Products of four different manufacturers were purchased and tested during this study. A total 8 number of ten vaccines were investigated, of which six were of the same brand (vaccines 9 number 1 to 6), but purchased in different countries (Hungary, Israel, Malta and United States 10 of America) or were from batches dated back to 1992, 1994 and 2006 (Table 1 ). All modified 11 live CD vaccines were stored at the recommended temperature of 4 °C. 12 13
RNA purification 14
Vaccines were prepared according to the protocol provided by each manufacturer. 
Primers 21
The primers used in the present study were designed using the Primer Designer 4 software 22 
RT-PCRs and RFLP analysis 18
The RT-PCRs resulted amplicons of the expected size (Table 1) were purchased in different countries as well, such as Hungary, Israel, Malta and the UnitedM a n u s c r i p t
States of America (Table 1) . The RFLP test unequivocally resulted in undigested amplicons in 1 case of all batches from different time and geographical origin. 2 3
Genetic analyses 4
To identify the strain present in the Vanguard vaccines, primers were designed to cover more 5 than half of the viral genome. The nucleotide sequences of all CDV genes, except the highly 6 conserved L gene were determined. The genetic analyses of all investigated genes of the 7
Vanguard vaccines ( Table 1 ) have revealed that the virus strain present in all of them is more 8 closely related to different wild-type strains from the America-2 group, than to the one stated 9
by the manufacturer (Snyder Hill strain) or any of the viruses from the group of vaccine 10 strains ( Table 2) . As a next step the full nucleotide sequences of the highly variable H gene of 11 all vaccine brands currently used in Hungary were included in the study (Table 1) . Since the 12 obtained nucleotide sequences of vaccines 1 to 6 turned out to be 100% similar in case of all 13 batches, the subsequent investigations performed on other domains of the virus genome were 14 carried out using only vaccine number 6. According to the investigation of the complete 15 sequence of the H gene, the investigated virus strain was not positioned anywhere close to the 16 Snyder Hill strain, but it showed a significantly higher similarity to a lesser panda isolate 17 (99.45%) and a wild-type strain (98.90%) isolated from a naturally infected dog (strain 25259, 18 accession number: AY964114) in North America ( have been raised since at least 1992, it is possible that this recently and apparently 2 successfully attenuated wild-type strain could provide, at least theoretically, a better 3 protection against the currently circulating wild-type CDV strains. 4
On the other hand, these findings suggest that the previously described PsiI-based 5 identification of America-1 (vaccine) strains could lead to diagnostically false results in case 6 of animals recently vaccinated with any Vanguard vaccine, or in case of animals with 7 uncertain vaccination history that could have been vaccinated with a Vanguard vaccine. 8 9
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Follow-up 14
Following the notification of the research group, the manufacturer has performed the 15 sequencing of the vaccine master-seed strain used globally for the production of the vaccine. 16
The work has resulted in a regulatory review of, and a change in, the strain designation in the 17 Small 38, 787-797. 8 9 Martella, V., Elia, G., Lucente, M.S., Decaro, N., Lorusso, E., Bányai, K., Blixenkrone-10 M a n u s c r i p t A c c e p t e d M a n u s c r i p t 
